We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

STANDARD DIAGNOSTICS INC.

Standard Diagnostics develops rapid diagnostic tests that make it possible to diagnose various diseases at an earlier... read more Featured Products: More products

Download Mobile App




Immuno-Magnetic Agglutination Assay Detects Dengue Virus Antigen

By LabMedica International staff writers
Posted on 09 Mar 2020
Dengue virus (DENV) is the most important arbovirus worldwide, causing infections in endemic countries and returning travellers from these areas. More...
Rapid diagnostic tests are needed to improve patient management and monitor local transmission. The detection of DENV non-structural protein 1 (NS1) is a useful tool for the diagnosis.

Immuno-magnetic agglutination (IMA) assays are newly developed methods that use magnetic particles coated with capture molecules (e.g. antibodies, ligands, nucleotides) that bind specifically to the target biomarker, forming clusters that enable the detection. Different assays have been developed for the detection of pathogens, small molecules and proteins.

Clinical microbiologists at the Hospital Clinic of Barcelona (Barcelona, Spain) and their colleagues analyzed a panel of 135 serum samples from travelers returning from dengue endemic countries: 74 DENV positive samples including the four DENV serotypes, 26 Zika virus positive samples, 25 chikungunya virus positive samples, five malaria positive samples and five negative samples.

The team tested the samples by three different methods for detection of DENV NS1 antigen: SD Dengue NS1 Ag ELISA is an enzyme-linked immunosorbent assay for the qualitative detection of NS1 antigen in human serum (Standard Diagnostic Inc, Yongin, Korea), SD BIOLINE Dengue Duo is a rapid immunochromatographic test (ICT) that detects both DENV NS1 antigen and antibodies against DENV (IgM/IgG) in human serum, plasma or whole blood, and ViroTrack Dengue Acute, a rapid and semi-quantitative microfluidic DENV NS1 detection method based on IMA technology (BluSense Diagnostics, Copenhagen, Denmark).

The scientists reported that sensitivity values were higher with the ELISA (97.2%), followed by the IMA assay (91.9%) and the ICT (68.1%). Specificity was 100% for ELISA and ICT and 98.4% for the IMA test. One ZIKV positive sample tested positive in IMA assay. This sample was obtained two days after the onset of the symptoms and tested positive for ZIKV and negative for DENV and CHIKV by real-time RT-PCR. This apparent cross-reactivity was not observed in the other 25 ZIKV positive samples tested. All methods showed high specificity (98.4% for ViroTrack Dengue Acute and 100% for both SD Dengue NS1 Ag ELISA and SD BIOLINE Dengue Duo). SD Dengue NS1 Ag ELISA and ViroTrack Dengue Acute only failed to detect a samples positive for DENV-2.

The authors concluded that ViroTrack Dengue Acute is a sensitive and specific assay for DENV NS1 detection. It provides faster results than the ELISA method and a better performance than the rapid immunochromatographic tests. ViroTrack Dengue Acute could represent a valuable tool for rapid diagnosis of DENV infections in returning travellers from endemic countries. The study was published on February 18, 2020 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Hospital Clinic of Barcelona
Standard Diagnostic Inc
BluSense Diagnostics



New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.